Blood pressure control in hypertensive patients in Irish primary care practices

Journal of Clinical Hypertension

Volumn 11, Issue 8, 2009, Pages 432-440

  Buckley, Brendan ^a   Shanahan, Eamonn ^b   Colwell, Niall ^c   Turgonyi, Eva ^d   Bramlage, Peter ^e   Perry, Ivan J ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b Farranfore Medical Centre   (Ireland)

^c Sanofi Aventis Ireland Ltd ^*

^d Institute for Cardiovascular Pharmacology   (Ireland)

^e Institute for Cardiovascular Pharmacology and Epidemiology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; ARTICLE; AWARENESS; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET; DISEASE DURATION; EXERCISE; FEMALE; HEALTH SERVICE; HUMAN; HYPERTENSION; IRELAND; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COMBINED MODALITY THERAPY; DIET THERAPY; EXERCISE THERAPY; FEMALE; HEALTH SURVEYS; HUMANS; HYPERTENSION; IRELAND; LIFE STYLE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; TREATMENT OUTCOME;

EID: 69049111949     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00151.x     Document Type: Article

References (27)

1. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289:2363-2369.
2. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet. 2006;367:1747-1757.
3. Stolk P, Van Wijk BL, Leufkens HG, et al. Between-country variation in the utilization of antihypertensive agents: Guidelines and clinical practice. J Hum Hypertens. 2006;20:917-922.
4. Kearney PM, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: A systematic review. J Hypertens. 2004;22:11-19.
5. Sharma AM, Wittchen HU, Kirch W, et al. High prevalence and poor control of hypertension in primary care: Cross-sectional study. J Hypertens. 2004;22:479-486.
6. Bramlage P, Thoenes M, Kirch W, et al. Clinical practice and recent recommendations in hypertension management - reporting a gap in a global survey of 1259 primary care physicians in 17 countries. Curr Med Res Opin. 2007;23:783-791.
7. Moser M, Franklin SS. Hypertension management: Results of a new national survey for the hypertension education foundation: Harris interactive. J Clin Hypertens (Greenwich). 2007;9:316-323.
8. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135:825-834.
9. Oliveria SA, Lapuerta P, McCarthy BD, et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med. 2002;162:413-420.
10. Moser M. Physician or clinical inertia: What is it? Is it really a problem? And what can be done about it? J Clin Hypertens (Greenwich). 2009;11:1-4.
11. Bennett K, Kabir Z, Unal B, et al. Explaining the recent decrease in coronary heart disease mortality rates in Ireland, 1985-2000. J Epidemiol Community Health. 2006;60:322-327.
12. Scholes S, Prescott A, Bajekal M. Health and Lifestyle Indicators for Strategic Health Authorities 1994-2002. London: Department of Health (UK); 2004.
13. Creagh D, Neilson S, Collins A, et al. Established cardiovascular disease and CVD risk factors in a primary care population of middle-aged Irish men and women. Ir Med J. 2002;95:298-301.
14. Flanagan K. Goals for treating hypertension in general practice. Clin Focus. 2008;8:4-8.
15. O'Brien E, Waeber B, Parati G, et al. Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ. 2001;322:531-536.
16. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
17. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289:2560-2571.
18. Williams B, Poulter NR, Brown MJ, et al. British HYPERTENSION Society guidelines for hypertension management 2004 (BHS-IV): Summary. BMJ. 2004;328:634-640.
19. Euro Consumer Health Index 2008. http://www.healthpowerhouse.com/files/ euro-heart-index-2008.pdf Accessed December 15, 2008.
20. Shelley E, Daly L, Collins C, et al. Cardiovascular risk factor changes in the Kilkenny Health Project. A community health promotion programme. Eur Heart J. 1995;16:752-760.
21. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
22. Bangalore S, Messerli FH, Kostis JB, et al. Cardiovascular protection using beta-blockers: A critical review of the evidence. J Am Coll Cardiol. 2007;50:563-572.
23. Gu Q, Paulose-Ram R, Dillon C, et al. Antihypertensive medication use among US adults with hypertension. Circulation. 2006;113:213-221.
24. Kassler-Taub K, Littlejohn T, Elliott W, et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens. 1998;11:445-453.
25. Mancia G, Korlipara K, van Rossum P, et al. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit. 2002;7:135-142.
26. Leahy J. Heartwatch - the national programm in general practice for the secondary prevention of cardiovascular disease in Ireland. Heartwise. 2006;16:15-18.
27. Moebus S, Hanisch JU, Neuhäuser M, et al. Assessing the Metabolic Syndrome according to NCEP ATP III in Germany: Feasibility of a two step approach in 1 550 randomly selected primary health care practices. GMS. 2006;4:DOc7 (20061009).